I thought we'd get a bump after the lull in the second quarter. Disappointing that coverage growth stalled as well. I like that they recognize the deficiency in sales growth and were active in correcting this. I like that they reviewed the sales pipeline removing static leads, that gives some encouragement that those that remain are of a more solid stature. I suspect that once the sales start to fall in line the growth will be fairly quick, there will be a point where enough hospitals have the units that it will become standard of care and force the others to follow suit. Its at what point that occurs that's critical. Renewals and the accompanying price increase does validate the early adopters decision to go with Soza as they must be making money if they are happy to pay the higher prices.
Next quarter, lets hope!
IPD Price at posting:
4.2¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)